Cover of When to suspect adrenal insufficiency

When to suspect adrenal insufficiency

Adrenal insufficiency: identification and management

Evidence review B

NICE Guideline, No. 243

London: National Institute for Health and Care Excellence (NICE); .
ISBN-13: 978-1-4731-6464-2
Copyright © NICE 2024.

1. When to suspect adrenal insufficiency

1.1. Review question

When should adrenal insufficiency be suspected (for example, based on risk factors or symptoms)?

1.1.1. Introduction

Whilst adrenal insufficiency is rare, not diagnosing it has fatal consequences, indeed some patients present with adrenal crisis, hence healthcare professionals should be aware of the risks factors and signs and symptoms associated with this condition.

Primary adrenal Insufficiency: Addis

on’s disease is the most common cause in adults, and congenital adrenal hyperplasia is the most common cause in children.

Secondary adrenal insufficiency: caused by inadequate adrenocorticotropic hormone production by the pituitary gland, often because of treatment for pituitary disease, or from pituitary tumours and their treatment)

Tertiary adrenal insufficiency: caused by inadequate corticotrophin-releasing hormone production by the hypothalamus. This can be because of treatment for tumours in the hypothalamus or adjoining structures, or more commonly because of administration of glucocorticoids for more than 4 weeks causing hypothalamic-pituitary-adrenal axis [HPA-axis] suppression). Stopping glucocorticoids abruptly may also cause adrenal insufficiency.

Some medicines may cause adrenal insufficiency, such as opioids, checkpoint inhibitors (used increasingly for treating cancer), and medicines inhibiting cortisol clearance such as antifungals and antiretrovirals.

There are number of signs and symptoms for AI and factors that can cause AI (risk factors); however, their ability to discriminate AI accurately enough to make a differential diagnosis and begin treatment is uncertain. The aim of this review is to determine whether these signs, symptoms and risk factors can be as prompts for health care professionals to consider a diagnosis of adrenal insufficiency to initiate treatment in a timely way to prevent death or significant morbidity.

1.1.2. Summary of the protocol

For full details see the review protocol in Appendix A.

Table Icon

Table 1

PICO characteristics of review question.

1.1.3. Methods and process

This evidence review was developed using the methods and process described in Developing NICE guidelines: the manual. Methods specific to this review question are described in the review protocol in Appendix A and the methods document.

Declarations of interest were recorded according to NICE’s conflicts of interest policy.

1.1.4. Diagnostic evidence

1.1.4.1. Included studies
Signs and symptoms

A search was conducted for cross-sectional (single gate) studies reporting the diagnostic accuracy of signs and symptoms to identify whether adrenal insufficiency is present as indicated by the reference standard (clinical diagnosis of adrenal insufficiency by a specialist, short Synacthen test (standard and low dose), or insulin tolerance test).

Six studies were included in the review;15, 7 these are summarised in Table 2 below. Evidence from these studies is summarised in the clinical evidence summary below in Table 313 and the references are detailed in the References section. Evidence was identified for low blood pressure, hyperpigmentation, lethargy, salt craving, weight loss, hyponatraemia, hyperkalaemia, nausea, vomiting and diarrhoea. A variety of reference standard tests and cut-offs were used to identify adrenal insufficiency and one study used more than one reference standard. Three studies were based on people with HIV/AIDS, one study was based on people with dermatological conditions using topical corticosteroids, one study was based on people with suspected tuberculosis and one study was based on people with liver cirrhosis. No studies were identified in children.

The assessment of the evidence quality was conducted with emphasis on test sensitivity and specificity as this was identified by the committee as the primary measure in guiding decision-making. The committee set clinical decision thresholds as sensitivity/specificity 90% and 70% above which a test would be recommended and 60% and 50% below which a test is of no clinical use.

Risk factors

A search was conducted for prospective cohort studies with multivariable analysis reporting the predictive value of risk factors for adrenal insufficiency. No evidence was identified.

See also the study selection flow chart in Appendix C, sensitivity and specificity forest plots in Appendix E, and study evidence tables in Appendix D.

1.1.4.2. Excluded studies

See the excluded studies list in Appendix I.

1.1.5. Summary of studies included in the diagnostic evidence

Table Icon

Table 2

Summary of studies included in the evidence review of signs and symptoms.

See Appendix D for full evidence tables.

1.1.6. Summary of the diagnostic evidence

Table Icon

Table 3

Clinical evidence summary: low blood pressure (hypotension inclusion postural hypotension).

Table Icon

Table 4

Clinical evidence summary: hyperpigmentation.

Table Icon

Table 5

Clinical evidence summary: lethargy.

Table Icon

Table 6

Clinical evidence summary: salt craving.

Table Icon

Table 7

Clinical evidence summary: weight loss.

Table Icon

Table 8

Clinical evidence summary: Hyponatraemia (serum sodium <135 mEq/L) for diagnosing adrenal insufficiency.

Table Icon

Table 9

Clinical evidence summary: Hyperkalaemia (serum Potassium >5 mEq/L) for diagnosing adrenal insufficiency.

Table Icon

Table 10

Clinical evidence summary: nausea and vomiting for diagnosing adrenal insufficiency.

Table Icon

Table 11

Clinical evidence summary: nausea for diagnosing adrenal insufficiency.

Table Icon

Table 12

Clinical evidence summary: vomiting for diagnosing adrenal insufficiency.

Table Icon

Table 13

Clinical evidence summary: Diarrhoea for diagnosing adrenal insufficiency.

See appendix F for full details of Diagnostic evidence.

1.1.7. Economic evidence

1.1.7.1. Included studies

No health economic studies were included.

1.1.7.2. Excluded studies

No relevant health economic studies were excluded due to assessment of limited applicability or methodological limitations.

See also the health economic study selection flow chart in Appendix F.

1.1.8. Economic model

This area was not prioritised for new cost-effectiveness analysis.

1.2. The committee's discussion and interpretation of the evidence

There was limited evidence for this review question, so the committee also used their clinical knowledge and experience to make the recommendations.

1.2.1. The outcomes that matter most

Signs and symptoms review

The committee considered the diagnostic measures of sensitivity and specificity for the signs and symptoms that are associated with adrenal insufficiency, or that predict its occurrence. Clinical decision thresholds were set by the committee as sensitivity/specificity=0.9 and 0.7 above which a test would be recommended and 0.6 and 0.5 below which a test is of no clinical use. The committee prioritised sensitivity over specificity because the signs and symptoms would be used to help select those suspected of having adrenal insufficiency, in whom further investigation and timely treatment may be required. As there was sufficient sensitivity and specificity data available, no association data was included in the review.

Risk factors review

The committee considered association data (such as adjusted hazard ratios, risk ratios or odds ratios) along with diagnostic accuracy data of any risk prediction tools to identify the association and predictive accuracy of specific factors or patient characteristics that may lead to developing adrenal insufficiency. No relevant evidence was identified.

1.2.2. The quality of the evidence

Signs and symptoms review

A search was conducted for cross-sectional (single gate) studies reporting the diagnostic accuracy of signs and symptoms to identify whether adrenal insufficiency is present. Evidence was very limited, and six studies were included in the review. Evidence was identified for the following signs and symptoms: low blood pressure, hyperpigmentation, lethargy, salt craving, weight loss, hyponatraemia, hyperkalaemia, nausea, vomiting and diarrhoea. No evidence was identified for hypoglycaemia or failure to respond to initial treatments.

Evidence was from a mix of populations. Three studies were based on people with HIV/AIDS, one study was based on people with dermatological conditions using topical corticosteroids, one study was based on people with suspected tuberculosis and one study was based on people with liver cirrhosis. All studies were conducted in adults and no studies were identified for children.

A variety of reference standard tests and cut-offs were used to identify adrenal insufficiency and one study used more than one reference standard for diagnosis. The majority of studies used the Short Synacthen Test (either the standard or low dose).

All evidence was rated very low quality due to the risk of bias and imprecision around the effect estimate. Risk of bias was rated very high due to unclear recruitment strategies (whether random/consecutive), uncertainty around whether the sign/symptom was recorded without knowledge of the diagnosis and vice versa and unclear timing between the recording of the sign/symptom and the diagnosis. Many outcomes were downgraded for imprecision due to small study sizes and the confidence intervals crossing the decision thresholds, indicating conflicting interpretations of the result.

Meta-analysis of the data was not possible due to the differences in populations, reference standards and the cortisol cut-offs used, meaning that all results were based on small individual studies.

Risk factors review

A search was conducted for prospective cohort studies with multivariable analysis reporting the predictive value of risk factors for adrenal insufficiency. However, no evidence was identified so the committee used their clinical knowledge and experience to make the recommendations.

1.2.3. Benefits and harms

The committee discussed the evidence base available for the signs and symptoms review. Evidence was identified for the following signs and symptoms: low blood pressure (3 studies), hyperpigmentation (2 studies), lethargy (5 studies), salt craving (2 studies), weight loss (4 studies), hyponatraemia (2 studies), hyperkalaemia (1 study), nausea (2 studies, vomiting (2 studies), nausea and vomiting combined (1 study) and diarrhoea (2 studies). Overall, the evidence was reported in six studies. However, one study reported each sign/symptom at four different definitions of adrenal insufficiency and cut-offs so there are many more outcomes included.

The committee noted that the populations in the included studies were very specific (HIV, TB and liver cirrhosis) and were unsure how relevant the evidence was to make recommendations for a general adrenal insufficiency population.

The assessment of the evidence quality was conducted with emphasis on test sensitivity and specificity as this was identified by the committee as the primary measure in guiding decision-making. The committee set clinical decision thresholds as sensitivity/specificity 90% and 70% above which a test would be recommended and 60% and 50% below which a test is of no clinical use. Using these thresholds none of the signs and symptoms met the agreed threshold of 90% for sensitivity to base recommendations. Several outcomes reached the specificity threshold of 70% however, when looking at the paired values together, none of these reached the sensitivity threshold which was considered of higher priority in clinical decision making. The committee noted the high specificity for hyperpigmentation and discussed it is common in people with primary AI and the clearest indicator for suspecting the condition. They noted this feature may not be easily recognised in people with black or brown skin and that clinicians should inspect buccal mucosa, surgical scars and ask the person if they have noticed any change to their skin.

Other symptoms also had a high specificity, such as hyperkalaemia but the committee noted these are very uncommon. Due to the limitations of the available evidence the committee decided to use their consensus opinion to formulate recommendations and agreed on a weaker ‘consider’ recommendation for the specific signs and symptoms indicative of adrenal insufficiency.

The committee agreed that the symptoms and signs associated with adrenal insufficiency were common to a range of conditions and this is partly why a diagnosis of adrenal insufficiency can be missed. Nevertheless, the committee agreed that when one or more of the symptoms, signs or features are present without an alternative explanation, it should raise suspicion of adrenal insufficiency amongst clinicians. They discussed that non-specific symptoms such as lethargy or diarrhoea are too general and might lead to over-testing, therefore these symptoms would also need to be persistent and other potential causes ruled out before warranting further investigation. The committee discussed the needs of young children and people not able to communicate how they are feeling, noting that clinicians and carers need to be vigilant in monitoring for signs of adrenal insufficiency as these can be subtle and easily missed.

The committee noted that hyponatraemia, whilst common, can be indicative of adrenal insufficiency if it occurs in conjunction with other symptoms listed. Hyponatraemia can be profound in primary adrenal insufficiency and associated with significant postural symptoms due to both glucocorticoid (GC) and mineralocorticoid deficiencies.

The committee also agreed through consensus opinion that features such as hypoglycaemia, faltering growth, hypotensive crisis, and differences in sex and development in children should also prompt consideration of adrenal insufficiency, especially when these are not in isolation. For example, hypoglycaemia by itself wouldn’t necessarily indicate adrenal insufficiency but if other causes have been excluded such as not being small for gestational age and other investigations as part of a hypoglycaemia screen have not shown other causes then adrenal insufficiency should be suspected, and the cortisol levels should be checked.

The committee decided to make consensus recommendations drawing on their experience of symptoms and signs seen in clinical practice, and their knowledge of the risk factors associated with medications and people with other co-existing conditions and comorbidities. The most common coexisting conditions include primary hypothyroidism and type 1 diabetes. However, clinicians should be aware that there are some rare co-exiting conditions such as Adrenoleukodystrophy and Adrenomyeloneuropathy where adrenal insufficiency should not be overlooked as investigations are often focussed on the conditions themselves and adrenal insufficiency is missed.

1.2.4. Cost-effectiveness and resource use

No economic evaluations were identified for this review question. Due to a lack of clinical evidence that was generalisable to all people with adrenal insufficiency, the committee made consensus recommendations that were reflective of current practice. These recommendations are therefore not expected to result in a significant resource impact.

1.2.5. Recommendations supported by this evidence review

This evidence review supports recommendations 1.2.1 to 1.2.4 and 1.9.6 to 1.9.7.

References

1.
Abbott M, Khoo SH, Hammer MR, Wilkins EG. Prevalence of cortisol deficiency in late HIV disease. The Journal of infection. 1995; 31(1):1–4 [PubMed: 8522825]
2.
Casanova-Cardiel L, Palacios-Jimenez N, Miralrio-Gomez G, Gaytan-Martinez J, Reyes-Garcia G, Mateos-Garcia E et al Can adrenal insufficiency be diagnosed on clinical and laboratory data basis in patients with AIDS? Proceedings of the Western Pharmacology Society. 2003; 46:103–108 [PubMed: 14699900]
3.
Hintong S, Phinyo P, Chuamanochan M, Phimphilai M, Manosroi W. Novel predictive model for adrenal insufficiency in dermatological patients with topical corticosteroids use: A cross-sectional study. International Journal of General Medicine. 2021; 14:8141–8147 [PMC free article: PMC8594898] [PubMed: 34803396]
4.
Mabuza LH, Sarpong DF. Indicators of adrenal insufficiency in TB-suspect patients presenting with signs and symptoms of adrenal insufficiency at three South African Hospitals in Pretoria. Open Public Health Journal. 2020; 13(1):178–187
5.
Naguib R, Fayed A, Abouelnaga S, Naguib H. Evaluation of adrenal function in hemodynamically stable patients with liver cirrhosis. Clinical and experimental hepatology. 2022; 8(1):78–83 [PMC free article: PMC8984798] [PubMed: 35415258]
6.
National Institute for Health and Care Excellence. Developing NICE guidelines: the manual. London. National Institute for Health and Care Excellence, 2014. Available from: https://www​.nice.org​.uk/process/pmg20/chapter/introduction [PubMed: 26677490]
7.
Wolff FH, Nhuch C, Cadore LP, Glitz CL, Lhullier F, Furlanetto TW. Low-dose adrenocorticotropin test in patients with the acquired immunodeficiency syndrome. The Brazilian journal of infectious diseases: an official publication of the Brazilian Society of Infectious Diseases. 2001; 5(2):53–59 [PubMed: 11493409]

Appendices

Appendix B. Literature search strategies

The literature searches for this review are detailed below and complied with the methodology outlined in Developing NICE guidelines: the manual.6

For more information, please see the Methodology review published as part of the accompanying documents for this guideline.

B.1. Clinical search literature search strategy

Searches were constructed using a PICO framework where population (P) terms were combined with Intervention (I) and in some cases Comparison (C) terms. Outcomes (O) are rarely used in search strategies as these concepts may not be indexed or described in the title or abstract and are therefore difficult to retrieve. Search filters were applied to the search where appropriate.

Download PDF (282K)

B.2. Health Economics literature search strategy

Health economic evidence was identified by conducting searches using terms for a broad Adrenal Insufficiency population. The following databases were searched: NHS Economic Evaluation Database (NHS EED - this ceased to be updated after 31st March 2015), Health Technology Assessment database (HTA - this ceased to be updated from 31st March 2018) and The International Network of Agencies for Health Technology Assessment (INAHTA). Searches for recent evidence were run on Medline and Embase from 2014 onwards.

Download PDF (158K)

Appendix C. Diagnostic evidence study selection

Download PDF (111K)

Appendix D. Diagnostic evidence

Download PDF (407K)

Appendix F. Economic evidence study selection

Download PDF (176K)

Appendix G. Economic evidence tables

None.

Appendix H. Health economic model

No original economic modelling was undertaken for this review question.

Appendix I. Excluded studies

I.1. Clinical studies

Table Icon

Table 16

Studies excluded from the clinical review.

I.2. Health Economic studies

None.